This invention is directed to methods of using compounds having the structure: ##STR00001## and including stereoisomers, solvates, and pharmaceutically acceptable salts thereof, wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 is independently selected from hydrogen, R.sup.5, R.sup.6, and R.sup.7; R.sup.5 is selected from alkyl, heteroalkyl, aryl and heteroaryl; R.sup.6 is selected from (R.sup.5).sub.n-alkylene, (R.sup.5).sub.n-heteroalkylene, (R.sup.5).sub.n-arylene and (R.sup.5).sub.n-heteroarylene; R.sup.7 is selected from (R.sup.6).sub.n-alkylene, (R.sup.6).sub.n-heteroalkylene, (R.sup.6).sub.n-arylene, and (R.sup.6).sub.n-heteroarylene; and n is selected from 0, 1, 2, 3, 4 and 5, where R.sup.1 and R.sup.2 may together form a heterocyclic structure including the nitrogen to which they are both attached, and R.sup.3 and R.sup.4 may together form a heterocyclic structure including the nitrogen to which they are both attached; and each of L.sup.1 and L.sup.2 is independently selected from -A1-A2-A3- where each of A1, A2, and A3 is independently selected from a direct bond, alkylene, heteroalkylene, arylene and heteroarylene. These compounds are useful in treating hyperproliferative disorders and inducing apoptosis.